Eli Lilly and Co (LLY)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Our last 30 days of resolved calls came true 43% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- Monthly momentum+10.5% over the past month+5
- 12-month trend+55% over the past year+6
- 52-week positionPressing 52-week highs+30
- QualityRevenue growing 50% y/y+10
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst is earnings, given the cluster of earnings-related headlines and the flagged October 29 date pointing to an upcoming report. Continuation likelihood is uncertain and roughly balanced, since pre-earnings positioning and broader macro volatility make a sustained directional move over the next few weeks no better than a coin flip. Informational only — not financial advice.
- Court rejects Novo bid to block Lilly obesity drug adsYahoo · 2026-10-27
- Jim Cramer is Bullish on These 5 StocksYahoo · 2026-10-27
- 4 Arthritis Drug Stocks Investors Should Monitor for Growth PotentialYahoo · 2026-10-27
- US Judge Denies Novo Nordisk Request To Block Eli Lilly Weight Loss Drug AdsYahoo · 2026-10-27
- What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings?Yahoo · 2026-10-27
Any AI summary is an interpretation of public news, not advice or a price target.